BDXNYSESurgical & Medical Instruments & ApparatusFiscal year ends September 30
BECTON DICKINSON & CO
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$190.74−1.01 (-0.53%)
Close on Oct 19, 2026
- Market cap
- $52.48B
- P/E (TTM)
- 57.6
- Dividend yield
- 2.18%
BECTON DICKINSON & CO revenue by segment
By business segment
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interventional | $5.47B | $5.38B | $5.29B | $5.22B | $5.11B | $5.02B | $5.05B | $4.98B | $4.92B | $4.90B | $4.80B | $4.74B | 23.5% | +7.0% |
| Medical | – | – | – | $11.46B | $11.14B | $10.77B | $10.46B | $10.07B | $9.79B | $9.67B | $9.58B | $9.50B | – | – |
| Life Sciences | – | – | $4.64B | $5.17B | $4.68B | $4.68B | $4.74B | $5.19B | $5.18B | $5.15B | $5.12B | $5.13B | – | – |
By product or service
By region
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U S [Member] | $13.58B | $13.38B | $13.24B | $12.79B | $11.86B | $11.86B | $11.99B | $11.66B | $11.42B | $11.31B | $11.13B | $11.11B | 58.4% | +14.5% |
| International | $9.68B | $9.62B | $9.52B | $9.05B | $7.96B | $8.21B | $8.65B | $8.52B | $8.40B | $8.41B | $8.36B | $8.26B | 41.6% | +21.6% |
From the segment and revenue-disaggregation notes of Becton Dickinson's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.